Not exactly. My focus was on thinking the some po

Not exactly. My focus was on thinking the some portion of the BK trials could be used toward FDA approval. As I stated in my conversations w TC, the US FDA approval is required before BK approaches anyone overseas for their approval. So if we need US trials, we are again relying on a large amount of NGIO funding thru common or preferred shares, and no further revenue will come from these deals until US trials are completed for FDA approval.